Document Detail

Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
MedLine Citation:
PMID:  16799657     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The diagnostic efficacy of Nuclear Matrix Protein-22 (NMP-22), bladder tumor antigen (BTA TRAK), and telomerase activity was evaluated in urine in a trial to assess their value in the detection of bladder cancer and to compare it to that of routine urine cytology. SUBJECTS AND METHODS: The study included 46 newly diagnosed bladder cancer patients, diagnosed by cystoscopy and histopathological typing, in addition to 20 patients with benign bladder lesions and 20 healthy age and sex matched volunteers as a control group. Fifty percent of the cancer patients (23/46) had proven bilharzial history. Most patients (27/46) had transitional cell carcinoma (TCC), 17/46 had squamous cell carcinoma (SCC), while only 2 patients had adenocarcinoma. A single freshly voided urine sample (approximately 100ml) was collected from each patient and control subject and aliquoted for each test. All assays were conducted according to the manufacturer's guidelines and the results were compared to those of urine cytology. RESULTS: The optimal cutoffs for NMP-22, BTA and telomerase activity as calculated by ROC curves were 12.1 U/ml, 78 U/ml, 0.48 (Ratio) respectively. The levels of the three parameters were significantly higher in the malignant group compared to either the benign group or normal controls, (p<0.001) and the positive rates were also higher in the malignant group for all 3 parameters. The overall sensitivity of urine cytology, NMP-22, BTA and telomerase was 54.3%, 91.3%, 100% and 80.4% respectively. For bilharzial cancer bladder respective sensitivities were 69.6%, 95.6%, 100% and 73.9%, while for nonbilharzial cancer bladder the respective sensitivities were 39.1%, 87%, 100% and 87%. The overall specificities with urine cytology, NMP-22, BTA and telomerase was 100%, 87.5%, 92.5% and 95.0%, respectively. Combined sensitivity of voided urine cytology with one or more of the 3 biomarkers, or the use of these biomarkers in double or triple combinations gave higher positivity than each biomarker alone. CONCLUSION: BTA showed the highest sensitivity in all the studied parameters in the bladder cancer group, bilharzial bladder cancer subgroup, and non bilharzial bladder subgroup, (100%), while the highest specificity was recorded with urine cytology (100%), followed by telomerase (95%), then BTA (92.5%), and lastly NMP- 22 (87.5%). Use of markers in combination with cytology, or in a panel, improved the sensitivity, and specificity.
Iman A Abd El Gawad; Heba S Moussa; Maha I Nasr; Emad H El Gemae; Amr M Masooud; Ibrahim K Ibrahim; Niveen M El Hifnawy
Related Documents :
1697047 - Brain metastasis from transitional cell carcinoma of the bladder--case report.
7834477 - Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the ...
16625287 - Synchronous primary carcinomas of the bladder and prostate.
10889567 - Secretory immunoglobulin a in the vesical urothelium of patients with neuropathic bladd...
7850307 - Written information for transurethral resection of the prostate--a national audit.
10379867 - Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large eur...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of the Egyptian National Cancer Institute     Volume:  17     ISSN:  1110-0362     ISO Abbreviation:  J Egypt Natl Canc Inst     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2006-06-26     Completed Date:  2007-06-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9424566     Medline TA:  J Egypt Natl Canc Inst     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  193-202     Citation Subset:  IM    
The Department of Clinical & Chemical Pathology, NCI, Cairo University.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / diagnosis,  urine
Antigens, Neoplasm / urine*
Carcinoma, Squamous Cell / diagnosis,  urine
Carcinoma, Transitional Cell / diagnosis,  urine
Middle Aged
Nuclear Proteins / urine*
Schistosomiasis haematobia / complications
Telomerase / urine*
Tumor Markers, Biological / urine*
Urinary Bladder Neoplasms / diagnosis*,  parasitology,  urine*
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Nuclear Proteins; 0/Tumor Markers, Biological; 0/bladder tumor-associated antigen; 0/nuclear matrix protein 22; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic polymorphism of folate and methionine metabolizing enzymes and their susceptibility to malig...
Next Document:  Planning of the internal mammary field based on lymphoscintigraphy localization before postoperative...